1. Home
  2. LBRDA vs PTGX Comparison

LBRDA vs PTGX Comparison

Compare LBRDA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Broadband Corporation

LBRDA

Liberty Broadband Corporation

HOLD

Current Price

$34.99

Market Cap

7.2B

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$119.17

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRDA
PTGX
Founded
2014
2006
Country
United States
United States
Employees
1900
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
6.4B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
LBRDA
PTGX
Price
$34.99
$119.17
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$108.23
AVG Volume (30 Days)
189.0K
749.6K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
N/A
N/A
Revenue This Year
N/A
$874.25
Revenue Next Year
$109.28
N/A
P/E Ratio
$8.39
$2,437.60
Revenue Growth
N/A
N/A
52 Week Low
$29.18
$49.86
52 Week High
$100.71
$126.25

Technical Indicators

Market Signals
Indicator
LBRDA
PTGX
Relative Strength Index (RSI) 56.76 65.24
Support Level $31.91 $94.48
Resistance Level $34.90 N/A
Average True Range (ATR) 1.59 4.97
MACD 0.54 1.29
Stochastic Oscillator 55.73 74.01

Price Performance

Historical Comparison
LBRDA
PTGX

About LBRDA Liberty Broadband Corporation

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: